Liver cancer treatment study for patients not eligible for surgery
Part of Cancer clinical trials.
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have liver cancer that can't be removed by surgery, and either you haven't had any treatment yet, or this is a first recurrence after a cure (with no follow-up treatment)
- Your liver is working well enough (Child-Pugh grade A) and there is enough healthy liver tissue (over 700 ml)
- The cancer is only in your liver (no spread to other organs), and you have at least one tumor that can be measured on a scan
- Your blood counts, liver, and kidney function are within safe limits (example: platelets at least 60, no severe anemia)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
This trial tests a combination of liver-directed therapy (TACE) with two drugs—bevacizumab (Avastin) and atezolizumab (Tecentriq)—as a first treatment for liver cancer that cannot be removed by surgery. The goal is to see if this approach helps shrink tumors and control the disease longer.
This trial tests combining a liver-directed treatment (TACE) with two medications (Camrelizumab and Apatinib) to see if it works better for people with liver cancer that cannot be surgically removed. It is for people who have not had any previous treatment for their cancer.
This trial tests whether adding two immunotherapy drugs (tremelimumab and durvalumab) to a standard liver cancer treatment called TACE can help people with liver cancer that cannot be removed by surgery. TACE uses tiny particles to block the blood supply to the tumor and delivers chemotherapy directly to the liver.
This trial tests a combination of three treatments—two immunotherapy/anti-cancer drugs (bevacizumab and atezolizumab) plus a catheter-based liver treatment (TACE-HAIC)—for people with unresectable hepatocellular carcinoma (liver cancer that cannot be surgically removed). The goal is to slow or shrink the cancer.
This trial compares two treatments for liver cancer that cannot be removed by surgery: SIRT (a type of internal radiation) and cTACE (a type of targeted chemo). It aims to see which is more effective for patients with limited tumor spread and good liver function.
Hear when a new Transarterial Chemoembolization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.